DiaSorin offre una linea completa di test dedicata alle malattie TORCH disponibile sui sistemi LIAISON®.
The LIAISON® Toxo IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to Toxoplasma gondii in human serum or plasma samples for screening of pregnant women. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® XL Toxo IgG Avidity assay uses chemiluminescent immunoassay (CLIA) technology for the determination of antigen-binding avidity of IgG antibodies to Toxoplasma gondii in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzer only.
The LIAISON® Toxo IgM assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to Toxoplasma gondii in human serum or plasma samples. The test has to be performed on the LIAISON® Analyzer.
The LIAISON® Rubella IgG assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to rubella virus in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Rubella IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of specific IgM antibodies to rubella virus in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgG II assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of specific IgG antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgM II assay uses chemiluminescence immunoassay (CLIA) technology for the semi-quantitative determination of specific IgM antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® CMV IgG Avidity II assay uses chemiluminescence immunoassay (CLIA) technology for the determination of antigen-binding avidity of IgG antibodies to hCMV in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family
The LIAISON® HSV-1/2 IgG assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to Herpes simplex virus Types 1 and/or 2 (HSV-1 and/or HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
LIAISON® HSV-1 Type Specific IgG assay is a chemiluminescent immunoassay (CLIA) to be used with the LIAISON® Analyzer for the qualitative determination of specific IgG antibodies to Herpes simplex virus Type 1 (HSV-1) in human serum. The test has to be performed on the LIAISON® Analyzer family.
The LIAISON® HSV-2 IgG assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to Herpes simplex virus Type 2 (HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® HSV-1/2 IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to Herpes simplex virus Types 1 and/or 2 (HSV-1 and/or HSV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Biotrin Parvovirus B19 IgG assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgG antibodies to parvovirus B19 in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Biotrin Parvovirus B19 IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific IgM antibodies to parvovirus B19 in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
Alcuni test diagnostici sono diventati particolarmente importanti in seguito all’introduzione, in molti paesi, di programmi di screening creati per identificare le donne in stato di gravidanza a rischio di infezioni materno-fetali.
Tali infezioni possono essere causate da virus quali: Toxoplasma, Parvovirus B19, Rubella, hCMV, Herpes simplex, appartenenti al cosiddetto pannello TORCH. Una volta che la malattia viene identificata, è possibile monitorarne il decorso e l’esito.
Spesso, gli organismi TORCH possono causare una lieve infezione nella madre e, nella peggiore delle ipotesi, portare a conseguenze ben più serie sul feto. Per questo motivo, la qualità del test sierologico è estremamente importante al fine di portare ad un’accurata diagnosi e ad una corretta gestione del paziente. Per migliorare la diagnosi sierologica è stato introdotto il test di avidità delle immunoglobuline G (IgG), in grado di identificare lo stadio dell’infezione e calcolare il rischio per il feto. Il poter distinguere le infezioni in corso da quelle pregresse, consente alle donne in stato di gravidanza di evitare stati d’ansia e trattamenti inutili.
